Bristol-Myers Squibb Company
Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases. Its portfolio is concentrated in oncology, hematology, immunology, cardiovascular, and neuroscience, with a mix of marketed products and pipeline assets designed to support long-term growth.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueImmuno-oncology, combination regimens, and cell-therapy products for solid tumors and blood cancers.
Anticoagulation and cardiac medicines, anchored by Eliquis and Camzyos.
Therapies for multiple myeloma, anemia, and other blood disorders, including legacy and growth products.
Autoimmune and inflammatory disease treatments sold to specialist prescribers and hospitals.
Royalties, alliance-related revenues, and non-core product or licensing income.
Customers
BMS sells primarily to wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies, with physician specialists driving much of the end demand. In the U.S., some products are also distributed through REMS-certified pharmacies or direct-to-patient offerings, reflecting tighter control for safety-sensitive medicines. Internationally, the company often relies on distributors that handle logistics, regulatory support, and promotion, which makes channel management and compliance important to execution.
Buy large volumes for downstream resale and inventory buffering; critical for U.S. and international channel access.
Dispense REMS-controlled and specialty medicines such as Revlimid, Pomalyst, and Camzyos.
Purchase and administer oncology, hematology, and infusion therapies used in specialist care settings.
Prescribe BMS medicines in oncology, cardiology, immunology, and hematology based on clinical evidence.
Influence formulary access, rebates, and reimbursement economics, especially in the U.S. and Europe.
Strategy
BMS is focused on concentrating capital and R&D on transformational medicines in areas where it believes it has a competitive edge, while improving operating efficiency across the enterprise. Recent moves show a strategy of supplementing internal research with licensing, collaborations, and acquisitions to deepen the pipeline in oncology, immunology, and radiopharmaceuticals. The company is also pushing commercial execution in key marketed products while using productivity initiatives to fund growth and shareholder returns.
Offsets patent and generic pressure by adding new assets and indications.
Eliquis, Opdivo, Reblozyl, Yervoy, and Orencia remain key revenue and cash drivers.
Improves margins and funds R&D and shareholder returns amid pricing pressure.
Creates a differentiated growth platform in precision oncology and diagnostics.
Geography
BMS reports two main revenue regions: the United States and International markets, with the U.S. representing the largest share and international revenue spread across many countries. The company notes that no single country outside the U.S. contributed more than 10% of total revenue, which reduces concentration but increases exposure to broad pricing, reimbursement, and foreign exchange differences. It also operates globally through distributors and local commercial structures, and it has expanded manufacturing and development capabilities in the U.S., including Indianapolis for radiopharmaceuticals.
Risks
BMS faces heavy exposure to pricing pressure, reimbursement changes, and loss of exclusivity on a concentrated set of products that drive most revenue and earnings. Its global footprint also exposes it to foreign exchange, regulatory, channel, and compliance risks, while its increasing use of AI, partnerships, and controlled distribution adds operational complexity. Generic competition, safety/regulatory actions, and cybersecurity remain important industry-wide threats.
- Dependence on key productsImpact: CriticalLikelihood: High
A majority of revenue and earnings comes from a small set of medicines, so any loss of exclusivity or demand decline can materially hurt results.
Exposure - Pricing pressure and reimbursement reformImpact: HighLikelihood: High
U.S. and international pricing restrictions, rebates, and channel changes can compress net selling prices and margins.
Exposure - Generic competition and loss of exclusivityImpact: HighLikelihood: High
Generic entrants can rapidly erode sales volumes and pricing for mature products.
Exposure - Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium
Business operations depend on digital systems and sensitive data, making outages or breaches potentially costly.
Exposure - Regulatory and controlled-distribution complexityImpact: MediumLikelihood: Low
REMS programs and country-specific distribution rules can limit access and increase operational burden.
Exposure
Accounting
Judgemental itemsBMS estimates rebates, chargebacks, discounts, and returns using payer mix, claims, and inventory data, which directly affects net revenue.
Impact: Can materially change quarterly and annual sales recognition
First-quarter unwinding of year-end inventory build can affect reported revenue independent of end demand.
Impact: Makes quarterly comparisons less representative of underlying demand
Royalties and collaboration income are reported separately from regional commercial sales and may be volatile.
Impact: Affects mix, growth rates, and comparability across periods
Recent deals can create acquired intangibles, contingent liabilities, and future impairment considerations.
Impact: Can affect amortization, balance sheet values, and earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
Revolution Medicines, Inc.
RVMD · Biological Products, (No Diagnostic Substances)
TG Therapeutics, Inc
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Last updated: 24/09/2026